Insights from Clinical Trials: Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma

被引：0

作者：

Lytvynova, Olga ^{[1
]}

Jwayyed, Jenna ^{[2
]}

Pastel, Daniel ^{[1
]}

Prasad, Rohan ^{[1
]}

Khouri, Jack ^{[3
]}

Williams, Louis ^{[3
]}

Mazzoni, Sandra ^{[3
]}

Raza, Shahzad ^{[3
]}

Anwer, Faiz ^{[3
]}

机构：

[1] Cleveland Clin Akron Gen, Dept Internal Med, Akron, OH 44307 USA

[2] INDIANA UNIV, Dept Anesthesiol, INDIANAPOLIS, IN 46202 USA

[3] Cleveland Clin Fdn, Taussig Canc Ctr, Cleveland Hts, OH 44106 USA

来源：

ANTIBODIES | 2024年 / 13卷 / 04期

关键词：

multiple myeloma; transplantation; drug regimen; immunotherapy; STEM-CELL TRANSPLANTATION; DARATUMUMAB PLUS BORTEZOMIB; DEXAMETHASONE D-VTD; OPEN-LABEL; SUBGROUP ANALYSIS; LENALIDOMIDE; PHASE-3; MULTICENTER; MAINTENANCE; THALIDOMIDE;

D O I：

10.3390/antib13040080

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Multiple myeloma (MM) is a hematological malignancy and poses significant therapeutic challenges. This review synthesizes evidence from pivotal clinical trials to guide induction treatment for transplant-eligible (TE), newly diagnosed MM (NDMM) patients. Emphasizing the evolution from three-drug to four-drug induction therapies, we highlight the integration of monoclonal antibodies, particularly CD38 recombinant monoclonal antibody agents, into treatment regimens. This analysis includes a comprehensive literature review of research from major databases and conferences conducted between 2010 and 2023, culminating in the detailed evaluation of 47 studies. The findings underscore the superiority of quadruple regimens in TE NDMM, notably those incorporating daratumumab, in achieving superior responses including progression-free survival (PFS), minimal residual disease (MRD) negativity, objective response rate (ORR), and overall survival (OS) when compared to triple-drug regimens. As treatment regimens evolve with additional agents, the improved outcomes with treatment-related adverse events should be carefully balanced. This review advocates for a paradigm shift towards quadruple induction therapies for TE NDMM, offers a detailed insight into the current landscape of MM treatment, and reinforces a new standard of care.

引用

页数：19

共 59 条

[1] Cancer Statistics Center. Published March 31, 2024
[2] International Myeloma Working Group (IMWG) Criteria for the Diagnosis of Multiple Myeloma. International Myeloma Foundation
[3] D'Agostino M., Cairns D.A., Lahuerta J.J., Wester R., Bertsch U., Waage A., Zamagni E., Mateos M.-V., Dall'Olio D., van de Donk N.W.C.J., Et al., Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: A European Myeloma Network (EMN) report within the HARMONY project, J. Clin. Oncol, 40, pp. 3406-3418, (2022)
[4] NCCN Clinical Practice Guidelines in Oncology
[5] Rajkumar S.V., Updated Diagnostic Criteria and Staging System for Multiple Myeloma, Am. Soc. Clin. Oncol. Educ. Book, 35, pp. e418-e423, (2016)
[6] Rajkumar S.V., Multiple myeloma: 2022 update on diagnosis, risk stratification, and management, Am. J. Hematol, 97, pp. 1086-1107, (2022)
[7] Rajkumar S.V., Dimopoulos M.A., Palumbo A., Blade J., Merlini G., Mateos M.-V., Kumar S., Hillengass J., Kastritis E., Richardson P., Et al., International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, 15, pp. e538-e548, (2014)
[8] Cowan A.J., Green D.J., Kwok M., Lee S., Coffey D.G., Holmberg L.A., Tuazon S., Gopal A.K., Libby E.N., Diagnosis and Management of Multiple Myeloma: A Review, JAMA, 327, pp. 464-477, (2022)
[9] Boussi L.S., Avigan Z.M., Rosenblatt J., Immunotherapy for the treatment of multiple myeloma, Front. Immunol, 13, (2022)
[10] Kegyes D., Constantinescu C., Vrancken L., Rasche L., Gregoire C., Tigu B., Gulei D., Dima D., Tanase A., Einsele H., Et al., Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?, J. Hematol. Oncol, 15, (2022)

← 1 2 3 4 5 6 →